Randall Lipps on Product Launch
From $OMCL Omnicell Q1 2026 Earnings Conference Call · · EARNMOAR
“Importantly, Titan XT represents a meaningful step as we advance toward autonomous medication management, and is the first step on the journey to connect every patient care area and pharmacy location with Omnisphere. We anticipate modest incremental Titan XT revenue in 2026, with initial hardware shipments planned to begin in the second half of the year, followed by a phased rollout of Omnisphere functionality in the first half of 2027.”
On , Randall Lipps, Founder, Executive Chairman, President & Chief Executive Officer at OMNICELL INC, spoke about Product Launch during $OMCL Omnicell Q1 2026 Earnings Conference Call on EARNMOAR.
About Randall Lipps
Randall Lipps, founder, executive chairman, president, and CEO of Omnicell, said on the company’s first-quarter 2026 earnings call that the company delivered results at the high end or above its previously issued guidance ranges across all key metrics. He reported total revenue of $310 million, non-GAAP EBITDA of $45 million, and non-GAAP earnings per share of 55 cents. Lipps stated that the company expects modest incremental Titan XT revenue in 2026, with initial hardware shipments in the second half of the year and a phased rollout of Omnisphere functionality in the first half of 2027. Lipps noted that customers considering an XTExtend upgrade are now evaluating Titan XT, which he said is increasing the size of deals. He also stated that a larger portion of future bookings is expected to come from competitive conversions, some of which may be sole-source agreements. In his closing remarks, Lipps expressed excitement about the company’s platform, which he described as empowered by AI, enterprise agents, and new robotics, and said these innovations are accelerating progress toward an autonomous pharmacy.